About Us
Our Mission.
Transforming GBM Treatment
At Infinova Biosciences, we are revolutionizing the treatment of brain cancers by tackling one of the most formidable challenges in medicine: delivering effective therapeutics across the blood-brain barrier (BBB) and deep into glioma tissue.
Fully aware of the complexity and historic nature of this challenge, we have made it our mission is to transform the landscape of glioblastoma treatment, a devastating and aggressive brain cancer with limited therapeutic options and poor survival outcomes.
At Infinova, we understand that addressing the complex challenges of biology demands innovative thinking and out-of-the-box creativity. This mindset is deeply embedded in our philosophy and drives the advancement of our technology.
Our Approach.
CAR-Neutrophil Drug Delivery Platform
Glioblastoma (GBM) biology poses several incredible barriers to the drug development process. At Infinova, we acknowledge that complex problems require creative solutions, and we attribute the innovation of our drug delivery platform to our full embrace of this philosophy.
Our highly unique approach to GBM treatment leverages the natural ability of neutrophils to not only penetrate the BBB but also infiltrate deep into tumor tissue. We start with chimeric antigen receptor (CAR)-expressing human pluripotent stem cells (hPSCs) that are differentiated to produce large quantities of CAR-neutrophils (CAR-NEs). These CAR-NEs are then loaded with drug-conjugated nanoparticles and infused intravenously.
Once in the body, our CAR-NEs cross the BBB, infiltrate deep into the core of glioblastoma tumors, and release their cytotoxic payload, inducing incredibly potent anti-tumor effects without risk of toxicities.
Click the link below to explore the biological foundation and important therapeutic details of this transformative technology.
Infinova's Leadership
Infinova Biosciences is led by a team of seasoned biotechnology veterans, each with decades of experience in building and advancing biotech companies. With a proven track record of delivering FDA-approved therapies across diverse disease areas, our leadership is committed to driving innovation and transforming glioblastoma treatment.
Tamara Jovonovich, PhD
Chief Executive Officer
Robert Lewis
Chief Operating Officer
Brian Cogely
Chief Financial Officer